Biomarin Pharmaceutical INC 8-K filings

BioMarin Pharmaceutical Inc. has entered into a settlement and license agreement with Ascendis Pharma A/S, resolving patent disputes and granting Ascendis rights to develop and commercialize TransCon CNP-based products.

BioMarin Pharmaceutical Inc. announced the discontinuation of VOXZOGO development for children with Noonan syndrome, citing feasibility and treatment landscape factors.

BioMarin Pharmaceutical Inc. announced the appointment of Dr. Robert Plenge to its Board of Directors, increasing the board size and adding scientific expertise.

BioMarin Pharmaceutical Inc. has successfully acquired Alesta Therapeutics B.V., integrating it as a wholly owned subsidiary.

BioMarin Pharmaceutical Inc. announced its definitive agreement to acquire Alesta Therapeutics, gaining access to ALE1, a potential first-in-class oral therapy for hypophosphatasia.

BioMarin Pharmaceutical Inc. has filed an amendment to its Form 8-K to include financial statements and pro forma information related to its acquisition of Amicus Therapeutics, Inc.

BioMarin Pharmaceutical stockholders approved the 2026 director elections, auditor ratification, executive compensation, and an increase in equity incentive plan shares.

BioMarin Pharmaceutical Inc. announced first quarter 2026 financial results, reporting $766 million in total revenues and increasing its full-year revenue guidance to $3.825 billion - $3.925 billion.

BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics for approximately $4.8 billion, significantly expanding its rare disease drug portfolio.

BioMarin Pharmaceutical Inc. announced that it has received French FDI clearance for its merger with Amicus Therapeutics, Inc., with the transaction expected to close on April 27, 2026.

BioMarin Pharmaceutical Inc. announced the discontinuation of certain Phase 2 trials for VOXZOGO due to safety concerns observed in external studies.

BioMarin Pharmaceutical Inc. announced robust fourth quarter and full-year 2025 financial results, including double-digit revenue growth, and confirmed the acquisition of Amicus Therapeutics to diversify and accelerate future revenues.

BioMarin Pharmaceutical Inc. has completed a private offering of $850 million in 5.500% Senior Notes due 2034 to finance its pending acquisition of Amicus Therapeutics, Inc. and related credit facilities.

BioMarin Pharmaceutical Inc. announced the pricing of $850 million in senior unsecured notes and completed syndication for $2 billion in term loans to finance its acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical Inc. announced preliminary 2025 revenues and a significant debt offering to fund its pending $5.2 billion acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical Inc. provided preliminary 2025 financial estimates, reporting approximately $3.2 billion in total revenues and a significant asset write-down for its ROCTAVIAN gene therapy.

BioMarin Pharmaceutical Inc. announced the discontinuation of its BMN 349 development program for Alpha-1 antitrypsin deficiency-associated liver disease.

BioMarin Pharmaceutical Inc. announced a definitive agreement to acquire Amicus Therapeutics for $4.8 billion in cash, expanding its rare disease portfolio with two marketed therapies and a late-stage candidate.

BioMarin Pharmaceutical Inc. announced the appointment of Rashmi Ramchandani as Vice President, Chief Accounting Officer, effective January 19, 2026.

BioMarin reports increased Q3 2025 revenues driven by VOXZOGO and PALYNZIQ, raises full-year guidance midpoint, and announces plans to divest ROCTAVIAN.

BioMarin Pharmaceutical Inc. anticipates approximately $221 million in pre-tax acquired In-Process Research and Development charges for the third quarter of 2025, impacting EPS by $1.10.

BioMarin Pharmaceutical Inc. announced the voluntary resignation of its Chief Accounting Officer, Erin Burkhart, effective September 2, 2025, with CFO Brian Mueller assuming interim principal accounting officer duties.

BioMarin Pharmaceutical Inc. reported robust second quarter 2025 financial results, exceeding expectations and raising full-year guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.

BioMarin Pharmaceutical Inc. announced the expansion of its Board of Directors and the appointment of Ian T. Clark as an independent director, effective August 1, 2025.

BioMarin Pharmaceutical Inc. held its 2025 Annual Meeting of Stockholders where they approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 8,000,000.

BioMarin Pharmaceutical Inc. will acquire Inozyme Pharma, Inc. for $270 million to strengthen its enzyme therapies portfolio with the addition of INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 Deficiency.

BioMarin announces a successful first quarter in 2025, marked by a 15% increase in total revenues to $745 million and significant growth in GAAP and non-GAAP earnings per share.

BioMarin Pharmaceutical Inc. amends and restates its bylaws to update advance notice provisions for stockholder nominations, director election procedures, and other corporate governance matters.

BioMarin Pharmaceutical Inc. has appointed Timothy P. Walbert to its Board of Directors, increasing the board size from eleven to twelve members, effective February 24, 2025.

BioMarin announces record full-year 2024 results driven by strong execution and operational transformation, setting the stage for double-digit revenue and profitability growth in 2025.